PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy

February 7, 2024

MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ:PETV & PETVW) (the “Company” or “PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates (i.e. Spryng™ with OsteoCushion™ Technology) into the joints of cats.

Read more at globenewswire.com

Related news for (PETVW)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.